Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wiktor performs well in heparin-free pilot:

This article was originally published in Clinica

Executive Summary

Medtronic's Wiktor stent has performed well in a pilot heparin- free implantation study. Over 400 patients were treated in the French pilot study which reduced heparisation from four weeks to none in five phases. Dr Joseph Elias from the Mulhouse Hospital said there were no deaths and none of the 422 patients needed CABG. Stent occlusion was 1%, except in phase IV (one week heparin) where it was 1.5%. With a good implantation technique, post-Wiktor stenting treatment with aspirin and ticlopidine seems to reduce in-hospital major complications. Low molecular weight heparin does not seem beneficial, he said. Heparin causes bleeding complications, a major draw-back to stenting.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT087692

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel